Abstract
SEmaglutide once-weekly randomized PRAgmatic Trial (SEPRA) (NCT03596450) is an ongoing, randomized, pragmatic trial comparing the effects of once-weekly subcutaneous semaglutide with other treatments for type 2 diabetes in routine clinical practice in the US. Traditionally, endpoints such as health care resource utilization and adherence are patient-reported in randomized trials. SEPRA utilized tokenization and linkage of study participants’ trial data to their claims data to support evaluation of supportive secondary endpoints. The objective of this project was to evaluate the overlap of participants with available claims data and compare baseline characteristics with the overall trial population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
